Navigation Links
Neurimmune Therapeutics Announces Advancement of Alzheimers Program into Preclinical Development
Date:8/18/2009

Zurich, Switzerland, August 18, 2009 / b3c newswire / -Neurimmune Therapeutics AG today announced that, following the successful completion of key research milestones, its lead human therapeutic antibody for Alzheimers disease has advanced into preclinical development, triggering milestone payments of an undisclosed amount from Biogen Idec (NASDAQ: BIIB). Neurimmune partnered with Biogen Idec for the worldwide development and commercialization of novel, fully human antibodies for the treatment of Alzheimers disease in November 2007. The alliance focuses on the development of antibodies that bind to amyloid beta (Abeta), a pathogenic molecule thought to cause neurodegeneration and loss of cognitive function in Alzheimers patients.

Neurimmunes unique Reverse Translational Medicine (RTM) technology platform combined with in-depth expertise in neuroscience played a critical role in moving the program forward. The fact that we could reach all preclinical milestones in such a short period of time shows that our RTM technology can significantly accelerate the transition from discovery to development of human monoclonal antibodies, said Jan Grimm, Chief Scientific Officer of Neurimmune Therapeutics.

The rapid advancement into preclinical development demonstrates the progress and productivity of our collaboration with Biogen Idec we are very happy to work with a partner that has such extensive and valuable experience in the development of biopharmaceuticals. The significant milestone payments also provide Neurimmune with additional financial stability to support the sustainable future development of our company, said Michael Salzmann, COO and General Manager of Neurimmune Therapeutics.

Biogen Idec is globally recognized as a leader in the development of innovative therapies for neurologic diseases, and this program is an important entry into Alzheimers disease for us, said Kenneth Rhodes, PhD, Vice President, Discovery Neurobiology, Biogen Idec. The rapid progression of this antibody is the result of a very effective joint collaboration, which capitalized on Neurimmunes novel RTM approach and our proven expertise in neuroscience and the development of therapeutic antibodies.

Alzheimers disease is the most prevalent age-related neurodegenerative disease affecting more than 15 million patients worldwide. There are currently no treatments approved to slow or stop the progression of the disease. Patients with Alzheimers disease experience the progressive loss of cognitive functions, particularly those related to memory, followed by death eight to 15 years after a progressive decline in their disease. The pathology of Alzheimers disease is characterized by distinctive features, including the deposition of Abeta in the form of senile plaques and the loss of specific neuronal populations in the brain.


About Neurimmune Therapeutics AG - www.neurimmune.com
Neurimmune Therapeutics AG is a Swiss biotechnology company dedicated to the identification of novel therapeutics for the treatment of human diseases with a focus on neurodegenerative disorders such as Alzheimers disease. Based on novel scientific concepts developed at the University of Zurich, Neurimmune Therapeutics has established a unique technology platform RTM (Reverse Translational Medicine) that supports Neurimmune Therapeutics translational research-focused drug discovery programs.

Neurimmune Therapeutics business strategy focuses on the discovery and development of human-derived antibodies through RTM at an early stage of the pharmaceutical value chain and partnering product candidates targeting significant markets and unmet medical needs with leading biopharmaceutical companies for later-stage development and marketing.

For further information please contact:
Michael Salzmann, PhD
COO & General Manager
Neurimmune Therapeutics AG
Wagistrasse 13, CH-8952 Schlieren
Zurich, Switzerland
phone +41 44 755 4646
fax +41 44 755 4647
michael.salzmann@neurimmune.com
'/>"/>
b3c newswire

Related biology news :

1. Amarna Therapeutics B.V. and TNO announce SVac research and development partnership
2. Continuous glucose monitoring technology -- special issue of Diabetes Technology and Therapeutics
3. NIH announces new program to develop therapeutics for rare and neglected diseases
4. Ocera Therapeutics licenses novel treatment for acute hepatic encephalopathy from UCLB
5. Tufts University professor receives IADR Pharmacology/Therapeutics/Toxicology Award
6. Acorda Therapeutics submits new drug application for Fampridine-SR in multiple sclerosis
7. A novel target for therapeutics against Staph infection
8. Bayhill Therapeutics and the Juvenile Diabetes Research Foundation announce research collaboration
9. Growing fuel and medicine: Advancing biofuels and plant-produced therapeutics
10. Sirtris review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery
11. Media invitation: 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... 21, 2017 Der weltweite Biobanking-Sektor ... Nach einem Gespräch mit mehr als 50 Vertretern aus verschiedenen ... überwinden gilt, um diese Prognose zu realisieren. ... Zu ... der finanziellen Mittel für die Biobank, die Implementierung Zeit ...
(Date:2/10/2017)... -- Research and Markets has announced the ... Scientific and Commercial Aspects" to their offering. ... Biomarkers play ... therapy for selection of treatment as well for monitoring the ... disease in modern medicine. Biochip/microarray technologies and next generation sequencing ...
(Date:2/8/2017)... Feb. 7, 2017 The biometrics market ... the confluence of organizations, desires to better authenticate ... systems (password and challenge questions), biometrics is quickly ... systems. The market is driven by use cases, ... consumer and enterprise uses cases, with consumer-facing use ...
Breaking Biology News(10 mins):
(Date:2/27/2017)... URBANDALE, Iowa (PRWEB) , ... February 27, 2017 , ... ... is following the advice of his grandfather, “Hire for attitude. Train for skill.” , ... State University star linebacker Jevohn Miller as a salesman. Zamzow is hoping to replicate ...
(Date:2/26/2017)... ... 2017 , ... Rob Lowe is a well recognized television personality, so it ... on issues that are important to the American public and important to society at ... a hot topic around the world for a few years. , The climate and ...
(Date:2/24/2017)... ... 2017 , ... A study recently published in Spine shows ... center (ASC) with satisfactory clinical and patient-reported outcomes, when compared to anterior cervical ... Lubinski, president of AxioMed, commented on the recent publication, stating, “We see cervical ...
(Date:2/24/2017)... ... February 24, 2017 , ... Chef Jodi Abel has ... Making stops in several cities, she gained a number of delicious recipes and ... Stellenbosch, a town in South Africa’s Western Cape province. It is internationally renowned ...
Breaking Biology Technology: